Intranasal salmon calcitonin reduces bone loss in the course of a long-term corticosteroid treatment in bullous diseases

F. Cappio, M. D. Colombo, R. Caputo

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Osteoporosis becomes a common pathologic feature in patients given a long-term corticosteroid treatment: actually, bone formation proves decreased, and bone resorption increased. Said reduced bone formation is ascribable to an inhibited osteoblastic function: on the contrary, increased bone resorption may be ascribed to a suppressed intestinal calcium absorption with a consequent secondary increase in the parathyroid hormone secretion. The present trial had the purpose of assessing the BMC (Bone Mineral Content) in 10 patients with bullous diseases, such as pemphigus and pemphigoid, in the course of treatment with corticosteroid agents and nasal spray salmon calcitonin (sCT). The patients, 3 males and 7 females, mean age 62.9 years (min 33, max 93) were given intranasal sCT at the dosage regimen of 200 IU/day/6 months. No patients had previously received corticosteroid treatment. Six patients were given betamethasone, and 4 methylprednisolone, compared thereafter with hydrocortisone; the minimum dose was 70 mg and the maximum dose 400 mg. To evaluate the BMC, the patients were subjected to a single photon absorption densitometry (SPA). Distal radius determinations were reasonably related with the axial skeleton BMC. Determinations were carried out at the start of the trial, at the 3rd month as well as the end of treatment. At the start of the trial, the mean BMC was 0.765 (±SE 0.056) calculated at the radial distal end; at the 6th month of treatment the mean BMC resulted to be 0.847 (±SE 0.059). Actually, as reported by various investigators, BMC may attain an over 10% loss in the course of a corticosteroid treatment, an evidence that is not encountered in the case of an intranasal sCT administration. On the ground of all above mentioned reasons, as well as in terms of compliance, intranasal spray sCT proves particularly indicated in patients subjected to a long-term corticosteroid treatment.

Original languageEnglish
JournalGiornale Italiano di Dermatologia e Venereologia
Volume125
Issue number12
Publication statusPublished - 1990

Fingerprint

salmon calcitonin
Adrenal Cortex Hormones
Bone Density
Bone and Bones
Bone Resorption
Osteogenesis
Therapeutics
Nasal Sprays
Betamethasone
Bullous Pemphigoid
Pemphigus
Densitometry
Intestinal Absorption
Methylprednisolone
Parathyroid Hormone
Photons
Skeleton
Osteoporosis
Compliance
Hydrocortisone

ASJC Scopus subject areas

  • Dermatology

Cite this

Intranasal salmon calcitonin reduces bone loss in the course of a long-term corticosteroid treatment in bullous diseases. / Cappio, F.; Colombo, M. D.; Caputo, R.

In: Giornale Italiano di Dermatologia e Venereologia, Vol. 125, No. 12, 1990.

Research output: Contribution to journalArticle

@article{031e88a900f24415b19f2c42e2dea113,
title = "Intranasal salmon calcitonin reduces bone loss in the course of a long-term corticosteroid treatment in bullous diseases",
abstract = "Osteoporosis becomes a common pathologic feature in patients given a long-term corticosteroid treatment: actually, bone formation proves decreased, and bone resorption increased. Said reduced bone formation is ascribable to an inhibited osteoblastic function: on the contrary, increased bone resorption may be ascribed to a suppressed intestinal calcium absorption with a consequent secondary increase in the parathyroid hormone secretion. The present trial had the purpose of assessing the BMC (Bone Mineral Content) in 10 patients with bullous diseases, such as pemphigus and pemphigoid, in the course of treatment with corticosteroid agents and nasal spray salmon calcitonin (sCT). The patients, 3 males and 7 females, mean age 62.9 years (min 33, max 93) were given intranasal sCT at the dosage regimen of 200 IU/day/6 months. No patients had previously received corticosteroid treatment. Six patients were given betamethasone, and 4 methylprednisolone, compared thereafter with hydrocortisone; the minimum dose was 70 mg and the maximum dose 400 mg. To evaluate the BMC, the patients were subjected to a single photon absorption densitometry (SPA). Distal radius determinations were reasonably related with the axial skeleton BMC. Determinations were carried out at the start of the trial, at the 3rd month as well as the end of treatment. At the start of the trial, the mean BMC was 0.765 (±SE 0.056) calculated at the radial distal end; at the 6th month of treatment the mean BMC resulted to be 0.847 (±SE 0.059). Actually, as reported by various investigators, BMC may attain an over 10{\%} loss in the course of a corticosteroid treatment, an evidence that is not encountered in the case of an intranasal sCT administration. On the ground of all above mentioned reasons, as well as in terms of compliance, intranasal spray sCT proves particularly indicated in patients subjected to a long-term corticosteroid treatment.",
author = "F. Cappio and Colombo, {M. D.} and R. Caputo",
year = "1990",
language = "English",
volume = "125",
journal = "Minerva dermatologica",
issn = "0392-0488",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "12",

}

TY - JOUR

T1 - Intranasal salmon calcitonin reduces bone loss in the course of a long-term corticosteroid treatment in bullous diseases

AU - Cappio, F.

AU - Colombo, M. D.

AU - Caputo, R.

PY - 1990

Y1 - 1990

N2 - Osteoporosis becomes a common pathologic feature in patients given a long-term corticosteroid treatment: actually, bone formation proves decreased, and bone resorption increased. Said reduced bone formation is ascribable to an inhibited osteoblastic function: on the contrary, increased bone resorption may be ascribed to a suppressed intestinal calcium absorption with a consequent secondary increase in the parathyroid hormone secretion. The present trial had the purpose of assessing the BMC (Bone Mineral Content) in 10 patients with bullous diseases, such as pemphigus and pemphigoid, in the course of treatment with corticosteroid agents and nasal spray salmon calcitonin (sCT). The patients, 3 males and 7 females, mean age 62.9 years (min 33, max 93) were given intranasal sCT at the dosage regimen of 200 IU/day/6 months. No patients had previously received corticosteroid treatment. Six patients were given betamethasone, and 4 methylprednisolone, compared thereafter with hydrocortisone; the minimum dose was 70 mg and the maximum dose 400 mg. To evaluate the BMC, the patients were subjected to a single photon absorption densitometry (SPA). Distal radius determinations were reasonably related with the axial skeleton BMC. Determinations were carried out at the start of the trial, at the 3rd month as well as the end of treatment. At the start of the trial, the mean BMC was 0.765 (±SE 0.056) calculated at the radial distal end; at the 6th month of treatment the mean BMC resulted to be 0.847 (±SE 0.059). Actually, as reported by various investigators, BMC may attain an over 10% loss in the course of a corticosteroid treatment, an evidence that is not encountered in the case of an intranasal sCT administration. On the ground of all above mentioned reasons, as well as in terms of compliance, intranasal spray sCT proves particularly indicated in patients subjected to a long-term corticosteroid treatment.

AB - Osteoporosis becomes a common pathologic feature in patients given a long-term corticosteroid treatment: actually, bone formation proves decreased, and bone resorption increased. Said reduced bone formation is ascribable to an inhibited osteoblastic function: on the contrary, increased bone resorption may be ascribed to a suppressed intestinal calcium absorption with a consequent secondary increase in the parathyroid hormone secretion. The present trial had the purpose of assessing the BMC (Bone Mineral Content) in 10 patients with bullous diseases, such as pemphigus and pemphigoid, in the course of treatment with corticosteroid agents and nasal spray salmon calcitonin (sCT). The patients, 3 males and 7 females, mean age 62.9 years (min 33, max 93) were given intranasal sCT at the dosage regimen of 200 IU/day/6 months. No patients had previously received corticosteroid treatment. Six patients were given betamethasone, and 4 methylprednisolone, compared thereafter with hydrocortisone; the minimum dose was 70 mg and the maximum dose 400 mg. To evaluate the BMC, the patients were subjected to a single photon absorption densitometry (SPA). Distal radius determinations were reasonably related with the axial skeleton BMC. Determinations were carried out at the start of the trial, at the 3rd month as well as the end of treatment. At the start of the trial, the mean BMC was 0.765 (±SE 0.056) calculated at the radial distal end; at the 6th month of treatment the mean BMC resulted to be 0.847 (±SE 0.059). Actually, as reported by various investigators, BMC may attain an over 10% loss in the course of a corticosteroid treatment, an evidence that is not encountered in the case of an intranasal sCT administration. On the ground of all above mentioned reasons, as well as in terms of compliance, intranasal spray sCT proves particularly indicated in patients subjected to a long-term corticosteroid treatment.

UR - http://www.scopus.com/inward/record.url?scp=0025580385&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025580385&partnerID=8YFLogxK

M3 - Article

C2 - 2091976

AN - SCOPUS:0025580385

VL - 125

JO - Minerva dermatologica

JF - Minerva dermatologica

SN - 0392-0488

IS - 12

ER -